PHM Protech Home Medical Corp

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a fast-growing and profitable
company focused on rolling-up annuity-based healthcare service companies in the
US and Canada, is well positioned to benefit from recently published articles in
the New England Journal of Medicine. The studies suggest up to one-third of the
strokes with undiagnosed causes may have resulted from atrial fibrillation, a
condition monitored by PHM. In both studies, using a longer home monitoring
duration significantly increased the number of patients prescribed
anticoagulants as a treatment, which in turn suggests an increase in PHM's
weekly home anticoagulant monitoring service market size. 


"We continue to see strong evidence that home-based diagnosis and treatment
saves patients lives and reduces overall costs to the US healthcare system,"
said Michael Dalsin, Chairman of PHM. "PHM is well positioned to take advantage
of the resulting increase in demand."


Details of the Accelerated Expiry Date of Select Warrants

PHM announced that the expiry date of the 5,958,047 warrants outstanding
exercisable at $0.22 per share, which have not yet been exercised, has been
accelerated to August 1, 2014 pursuant to the terms of the Warrant Certificates.
The warrants were originally issued pursuant to PHM's private placement of
20,295,176 units (each unit consisting of one common share and one-half of one
warrant) which closed on August 15, 2013, August 30, 2013 and September 6, 2013.
This is a result of the PHM share price achieving a volume-weighted average
trading price greater than $0.30 for more than 10 consecutive trading days. 


"This warrant acceleration, along with our existing strong balance sheet and
positive cash flow from operations, ensures that we won't have to seek equity
financing from the capital markets to close the next several acquisitions" said
Michael Dalsin, Chairman of PHM. "Our pipeline is growing and we continue to
work toward closing additional accretive acquisitions in the near term and
expect that we can use debt if necessary for any larger deals."


About PHM

PHM is an acquisition-oriented, fast-growing and profitable company servicing
patients with heart disease and other chronic health conditions. PHM is focused
on acquiring companies in a highly fragmented and developing market of small
privately-held companies servicing chronically ill patients with multiple
disease states caused mainly by age and obesity. Because of the new and highly
fragmented nature of the market, PHM is actively and successfully identifying
and evaluating profitable, annuity-based companies to acquire at favorable
prices in order to integrate their patient databases and technical expertise.
PHM's post-acquisition organic growth strategy is to increase annual revenue per
patient by offering multiple services to the same patient, consolidating the
patient's services and making life easier for the patient. The expected result
is growing EPS with each acquisition and growing revenue and profits from the
cross selling efforts.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.  


Forward-Looking Statements 

Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, difficulty integrating
newly acquired businesses, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected. This press release refers non-GAAP and non-IFRS financial
measures that do not have standardized meaning prescribed by GAAP or IFRS. PHM's
presentation of these financial measures may not be comparable to similarly
titled measures used by other companies. These financial measures are intended
to provide additional information to investors concerning PHM's performance. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Patient Home Monitoring Corp.
Michael Dalsin
Chairman
(323) 253-3055
www.phmhometesting.com

Patient Home Monitoring Corp. (TSXV:PHM)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Patient Home Monitoring Corp. (TSXV:PHM)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024